Allucent Appoints Steffany Cox as Chief Marketing Officer

AUGUST 22, 2022

Global biopharmaceutical services leader, Allucent, announced today the appointment of Steffany Cox as its chief marketing officer (CMO). In this C-Suite position, Cox will manage the company’s overall marketing strategy, help navigate market opportunities related to the company’s revenue, relationships, and reputation, and ensure the company’s mission and vision are reflected across all communications.

With 25+ years of experience in the healthcare industry and a passion for helping to improve the health and lives of people around the world, Cox will lead Allucent in developing and executing strategies to drive awareness, interest, and demand for the company’s comprehensive drug development solutions for small and mid-sized biotech companies.

“The transformational work being done by smaller biotech companies today holds immense potential to improve the future of healthcare, and therefore is of vital importance to the health and well-being of all of us,” said Cox. “The opportunity to be close to groundbreaking science, and part of a highly-qualified, dedicated team whose purpose is to help these companies bring needed new therapies to light is what attracted me to Allucent.”

Highlights of Cox’s career to date include:

  • Serving as the senior global vice president of Product Management and Segment Growth at Labcorp, where she spearheaded drug development growth strategy and innovation efforts for the company.
  • Heading-up a growth initiative focused on developing and launching a differentiated company-wide solution for Labcorp in the oncology space.
  • Holding various leadership roles with increasing responsibility at Labcorp / Covance, including leading global marketing and growth efforts for discovery and translational services (Precision Medicine), nutritional food and safety (Food Solutions), early development, and clinical development.
  • Leading U.S. and global marketing efforts for Eli Lilly in various therapeutic areas including cardiovascular disease and endocrinology.

“Steffany’s appointment comes at a critical and exciting time for our company, as we recently completed a series of strategic acquisitions and launched a new name and branding to reflect our unified business and its mission,” said Mark A. Goldberg, MD, chairman and chief executive officer, Allucent. “She brings a skill set, leadership qualities and strategic vision that will help propel Allucent forward to achieve continued success for our company, our partners and patients worldwide.”

Cox earned her B.S. in marketing from Indiana University Bloomington and an M.B.A. from Indiana Wesleyan University.

Share this: